Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Rogers

Showing results (71-80 of 196) with videos related to

Pageof 20
Sort By:
Antimicrobial Agents and Chemotherapy|March 16, 2026
Deciphering the multidrug resistance paradigm in <i>Candida auris</i>Darian J Santana, Nicholas C Cauldron, P David Rogers, et al.
Pharmacotherapy|November 25, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal AgentJeffrey M Rybak, Kayleigh R Marx, Andrew T Nishimoto, et al.
Environmental Microbiology|October 13, 2020
Mechanisms of triazole resistance in Aspergillus fumigatusAshley V Nywening, Jeffrey M Rybak, Phillip David Rogers, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2003
The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentrationP David Rogers, Robert E Kramer, Janice K Crews, et al.
The Annals of Pharmacotherapy|March 18, 2003
Voriconazole: a new triazole antifungal agentMargaret M Pearson, P David Rogers, John D Cleary, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and <i>CDR1</i> Expression in <i>Candida albicans</i>Andrew T Nishimoto, Qing Zhang, Brandon Hazlett, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 2006
Proteomic analysis of experimentally induced azole resistance in Candida glabrataP David Rogers, John-Paul Vermitsky, Thomas D Edlind, et al.
The Annals of Pharmacotherapy|December 23, 2011
Echinocandin use in the neonatal intensive care unitKelly E Caudle, Amanda G Inger, Dawn R Butler, et al.
BMJ Open|October 31, 2019
Barriers and facilitators to recommended physical activity in lower-limb osteoarthritis: protocol for a qualitative study exploring patients and physiotherapist perspectives using the theoretical domains framework and behaviour change taxonomyMatthew James Willett, Carolyn Greig, David Rogers, et al.
Antimicrobial Agents and Chemotherapy|November 4, 2009
An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicansClemens J Heilmann, Sabrina Schneider, Katherine S Barker, et al.
Pageof 20

Showing results (71-80 of 196) with videos related to

Sort By:
Pageof 20
Antimicrobial Agents and Chemotherapy|March 16, 2026
Deciphering the multidrug resistance paradigm in <i>Candida auris</i>Darian J Santana, Nicholas C Cauldron, P David Rogers, et al.
Pharmacotherapy|November 25, 2015
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal AgentJeffrey M Rybak, Kayleigh R Marx, Andrew T Nishimoto, et al.
Environmental Microbiology|October 13, 2020
Mechanisms of triazole resistance in Aspergillus fumigatusAshley V Nywening, Jeffrey M Rybak, Phillip David Rogers, et al.
The Journal of Antimicrobial Chemotherapy|February 4, 2003
The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentrationP David Rogers, Robert E Kramer, Janice K Crews, et al.
The Annals of Pharmacotherapy|March 18, 2003
Voriconazole: a new triazole antifungal agentMargaret M Pearson, P David Rogers, John D Cleary, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2019
Contribution of Clinically Derived Mutations in the Gene Encoding the Zinc Cluster Transcription Factor Mrr2 to Fluconazole Antifungal Resistance and <i>CDR1</i> Expression in <i>Candida albicans</i>Andrew T Nishimoto, Qing Zhang, Brandon Hazlett, et al.
The Journal of Antimicrobial Chemotherapy|June 1, 2006
Proteomic analysis of experimentally induced azole resistance in Candida glabrataP David Rogers, John-Paul Vermitsky, Thomas D Edlind, et al.
The Annals of Pharmacotherapy|December 23, 2011
Echinocandin use in the neonatal intensive care unitKelly E Caudle, Amanda G Inger, Dawn R Butler, et al.
BMJ Open|October 31, 2019
Barriers and facilitators to recommended physical activity in lower-limb osteoarthritis: protocol for a qualitative study exploring patients and physiotherapist perspectives using the theoretical domains framework and behaviour change taxonomyMatthew James Willett, Carolyn Greig, David Rogers, et al.
Antimicrobial Agents and Chemotherapy|November 4, 2009
An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicansClemens J Heilmann, Sabrina Schneider, Katherine S Barker, et al.
Pageof 20